Sanford Bernstein Analyst Echoes My Vytorin® Thoughts -- About 22 Months Later

Take a look at this -- mine, from May 28, 2008 -- now look at Sanford Bernstein Analyst Tim Anderson's note to investors, of today:

. . . .Vytorin will probably remain in permanent decline given the fierce competition both from alternative brands and generics. Also, technically it is true that there are as of yet no hard clinical outcomes on Vytorin to prove its value. This is what IMPROVE-IT is studying, but results won’t likely report out until 2013 and even if positive, it will probably be too late to really matter. . . .

Consider also my more-refined observations -- of November of last year, on Vytorin^® and IMPROVE-IT.

~~~~~~~~~~~~~~~

^{[Note: Jim Edwards also has a nice piece on Dr. Anderson's remarks.]}